Pre-existing disease clauses — when your insurer can deny a claim

The most frequent ground on which an Indian health-insurance claim is rejected is the pre-existing disease clause — the contractual carve-out by which an insurer denies cover for a condition that, on its case, the insured had at the time of taking the policy and did not disclose in the proposal form. The doctrinal anchor of the clause is the rule of uberrima fides — utmost good faith — which the Supreme Court applied to insurance contracts in Satwant Kaur Sandhu v New India Assurance Co Ltd, (2009) 8 SCC 316 and reaffirmed in Reliance Life Insurance Co Ltd v Rekhaben Nareshbhai Rathod, (2019) 6 SCC 175. The regulatory architecture is supplied by the IRDAI (Health Insurance) Regulations, 2016 and the IRDAI Health Insurance amendments and standardisation guidelines of 2019, which cap the look-back window on pre-existing disease, supply a standardised definition of the term, mandate the proposer's disclosure obligations, and — operationally most consequential — fix an eight-year moratorium period after which an insurer cannot contest a claim on the ground of non-disclosure or misrepresentation except for established fraud. The insurer's burden to prove materiality of the suppressed fact runs through LIC of India v Asha Goel, (2001) 2 SCC 160. The contra-proferentem rule operates on ambiguous policy terms — a doctrine the Supreme Court has applied to insurance contracts since General Assurance Society v Chandumull Jain, AIR 1966 SC 1644. This guide sets out the doctrine, the regulatory frame and the burden-and-standard architecture as they now operate.

Health insurance in India is, contractually, a one-year indemnity contract renewed at the option of the insured and underwritten at inception on the basis of the proposal form. The proposal form is the only document on which the insurer has assessed the risk; it is the document on which the underwriting premium has been fixed; and it is the document the insurer returns to at the time of a claim to test whether the loss falls within the cover. The pre-existing disease clause is the contractual mechanism by which the insurer can deny a claim on the ground that the condition for which the insured has been hospitalised, or its complications, was a condition the insured had at the time of taking the policy and did not disclose. The doctrine of uberrima fides supplies the legal anchor; the IRDAI Regulations supply the regulatory floor; the line of Supreme Court decisions from Mithoolal Nayak to Manmohan Nanda supplies the operational frame. This article sets out the doctrine, the regulatory architecture, the disclosure obligations of the proposer, the eight-year moratorium and the burden of proof on the insurer at the time of repudiation.

Uberrima fides — the doctrinal anchor

Insurance contracts are, in classical English law, contracts of the utmost good faith — uberrimae fidei. The rule, first articulated by Lord Mansfield in Carter v Boehm, (1766) 3 Burr 1905, casts a positive duty on the proposer to disclose to the insurer every fact material to the assessment of the risk, whether or not the insurer has specifically asked about it. The principle distinguishes insurance from ordinary commercial contracts where the rule is caveat emptor — silence is not, generally, misrepresentation. In insurance, by contrast, silence on a material fact can avoid the contract at the option of the insurer. The doctrine is partially codified in Section 19 of the Marine Insurance Act, 1963; in non-marine insurance it operates as a common-law principle that the Supreme Court has consistently applied. The general statement that "insurance contracts are contracts of utmost good faith and any non-disclosure of a material fact entitles the insurer to repudiate the contract" appears in dozens of Supreme Court and high-court judgments.

The Supreme Court in Satwant Kaur Sandhu v New India Assurance Co Ltd, (2009) 8 SCC 316 set out the doctrine in detail. The insured had taken a mediclaim policy, did not disclose that he had been suffering from chronic renal failure, and died of multiple organ failure shortly after the policy was taken. The insurer repudiated the claim under the pre-existing disease clause. The National Consumer Commission allowed the complaint; the Supreme Court reversed. K G Balakrishnan CJ, speaking for the Court, recorded that "in a contract of insurance any fact which would influence the mind of a prudent insurer in deciding whether to accept or not to accept the risk is a material fact". The test of materiality is the prudent-insurer test — not whether the proposer thought the fact was material, but whether a prudent insurer would have considered it material in assessing the risk. The Court held that the suppression of the renal failure was material and that the policy was rightly repudiated.

The Supreme Court reaffirmed and refined the doctrine in Reliance Life Insurance Co Ltd v Rekhaben Nareshbhai Rathod, (2019) 6 SCC 175. The case arose from a life-insurance policy on the husband's life; he had earlier taken policies from other insurers which he did not disclose in the proposal form to Reliance. He died within months. The insurer repudiated, the consumer commissions allowed the claim, and the Supreme Court reversed. D Y Chandrachud J (as the learned Chief Justice then was) recorded the principles — the contract is one of utmost good faith; the proposer is under a duty to disclose every material fact; the test of materiality is the prudent-insurer test; the consequence of non-disclosure is that the insurer is entitled to repudiate; the duty extends to the proposal form as completed and to any further information the insurer specifically requests. The case has become, alongside Satwant Kaur, the most-cited authority on the disclosure duty in Indian insurance law.

The proposer's disclosure obligations

The proposer's disclosure obligations in Indian health insurance run along three axes. First — answer truthfully every question in the proposal form. The proposal form is structured around a series of health-history questions: have you ever been diagnosed with, treated for or hospitalised for any of the listed conditions; do you have any congenital or hereditary condition; are you taking any medication on a regular basis; have you undergone any surgery; do you smoke or consume alcohol and in what quantity. The standardised question set was significantly extended and harmonised in the IRDAI Standardisation Guidelines of 2016 and the further amendments of 2019. The answer must be truthful as of the date of the proposal. An answer that was true when given but ceased to be true between the proposal and the inception of the policy must be updated by the proposer — the duty of disclosure is a continuing duty until the policy commences.

Second — disclose, even where not specifically asked, any condition that a prudent person would think material to the insurer's underwriting. The duty is wider than the questions in the proposal form. A history of cardiac investigation, even where no diagnosis was finally recorded; a history of cancer in remission; a recent symptom that the proposer has not yet investigated — all are matters that fall within the disclosure duty even where the proposal form does not specifically ask about them. The standard is what a reasonable proposer, with knowledge of the relevant facts, would have considered material to the insurer's assessment of the risk.

Third — verify the contents of the proposal form before signing. The Supreme Court in P C Chacko v LIC of India, (2008) 1 SCC 321 held that the proposer cannot disclaim the answers in the proposal form on the ground that the agent filled it in and she did not read it. The signature on the proposal form is taken as an affirmation of the contents. The proposer who allowed the agent to fill in the form, and signed it without reading, takes the consequences of any misstatement. The agent's knowledge does not, on the standard view, exonerate the proposer — although the Supreme Court has, in cases of clear agent fraud, allowed a different result on equitable grounds.

The IRDAI regulatory architecture

The Insurance Regulatory and Development Authority of India regulates the form, content and operation of health-insurance policies in India under the Insurance Regulatory and Development Authority Act, 1999. The IRDAI (Health Insurance) Regulations, 2016 fix the structural rules for health-insurance products — categories of policies, exclusions, claims-procedure, disclosures, free-look period, portability, and renewability. The IRDAI Standardisation in Health Insurance Guidelines, 2016 supply the standard definitions of terms used in policy contracts, including the definition of pre-existing disease. The 2019 amendments and the further IRDAI Master Circular on Standardisation in Health Insurance Business consolidated and extended the framework, with three changes that are operationally consequential.

First — the standardised definition of "pre-existing disease". Under the 2019 framework, "pre-existing disease" means any condition, ailment, injury or disease that is diagnosed by a physician within forty-eight months prior to the effective date of the policy issued by the insurer or its reinstatement, or for which medical advice or treatment was recommended by, or received from, a physician within forty-eight months prior to the effective date of the policy issued by the insurer or its reinstatement. The forty-eight-month look-back window is the regulatory cap — a condition that was diagnosed more than forty-eight months before the policy is, by definition, not a pre-existing disease for the purposes of the contract, even if the insured continues to have it. The standardised definition is binding on every insurer and cannot be diluted by the policy wording.

Second — the standardisation of exclusions. The IRDAI Guidelines on Standardisation of Exclusions in Health Insurance Contracts, 2019 list the standard PED waiting period — a maximum of forty-eight months from policy inception, after which a pre-existing disease that was disclosed at the time of the proposal becomes covered. The policy cannot impose a waiting period longer than forty-eight months on a disclosed pre-existing disease. The policy can, separately, exclude an undisclosed pre-existing disease in perpetuity — but the line is sharp and structurally important. A disclosed PED is excluded for a maximum of forty-eight months and then covered; an undisclosed PED can be excluded as long as the insurer can prove the non-disclosure was material.

Third — and operationally the most consequential — the eight-year moratorium period. Under the 2019 framework, after the completion of eight continuous years of coverage (the "moratorium period") under a health-insurance policy, no claim shall be contestable except for proven fraud and permanent exclusions specified in the policy contract. The moratorium runs from the inception of the policy with the insurer and continues across renewals; it is not interrupted by a portability change. The effect is that an insurer who has accepted premium for eight years cannot, in the ninth year, repudiate a claim on the ground of pre-existing disease or non-disclosure or misrepresentation — the only ground that survives the moratorium is proved fraud. The moratorium has substantially shifted the burden on long-renewed policies away from the insurer's contest of the disclosure and on to the insurer's contest of fraud, which is harder to establish.

The insurer's burden — Asha Goel and the materiality test

The doctrine of uberrima fides casts the disclosure duty on the proposer. The repudiation, however, is on the insurer's case — and the insurer who repudiates a claim on the ground of non-disclosure carries the burden of proving the non-disclosure and the materiality. The Supreme Court in LIC of India v Asha Goel, (2001) 2 SCC 160 set out the burden in the form in which it is most often cited. R P Sethi J recorded that the insurer is entitled to repudiate a policy on the ground of non-disclosure of a material fact only on proof — that the fact was within the proposer's knowledge, that the fact was material to the risk, that the proposer made the suppression knowingly, and that the policy was issued on the basis of the misstatement. The burden is on the insurer; the standard is the standard of proof in a civil case (preponderance of probabilities); the inference of knowledge cannot be drawn from medical records alone where the records do not show that the proposer was informed of the diagnosis.

The Asha Goel burden was applied and reinforced in Sulbha Prakash Motegaonkar v LIC of India, (2015) 9 SCC 35. The Supreme Court held that the insurer must prove the materiality on objective evidence, not on the bald assertion of the medical examiner; that the materiality test is the prudent-insurer test under Satwant Kaur; and that the suppression must be of a fact that is material to the assessment of the risk, not merely a peripheral or remote fact. Where the suppressed condition is unrelated to the cause of the claim — for instance, a remote history of an unrelated illness that has no causal connection with the hospitalisation — the repudiation may fail even where the non-disclosure is established, because the materiality of the suppression to the risk that crystallised is not made out. The Supreme Court in Manmohan Nanda v United India Assurance Co Ltd, (2022) 4 SCC 582 applied a related principle to an overseas travel insurance claim, holding that the materiality of the suppression must be tested against the fact-pattern of the claim and that an overly literal reading of the disclosure duty does not survive in cases where the causal connection is absent.

The historical anchor of the materiality doctrine is Mithoolal Nayak v LIC of India, AIR 1962 SC 814 — the foundational Supreme Court authority on non-disclosure and material misrepresentation in insurance, applied to a life policy where the insured had concealed a previous diagnosis of tuberculosis. The Mithoolal Nayak conditions — that the statements made are inaccurate or false, that the statements are on material matters or the proposer has suppressed facts which it was material to disclose, and that the suppressions were fraudulently made by the proposer — continue to be cited as the operational test, although the third limb (the fraudulent intent requirement) has been softened in the consumer-forum line of cases to read knowing or reckless non-disclosure, not necessarily fraudulent intent.

Contra proferentem — the ambiguity rule

A pre-existing disease clause that is ambiguous in its scope or operation is, on the established rule of construction of insurance contracts, to be read against the insurer who drafted it. The doctrine of contra proferentem has been applied to insurance contracts in India in a long line of cases beginning with General Assurance Society Ltd v Chandumull Jain, AIR 1966 SC 1644 — the foundational Supreme Court authority on the construction of policy clauses. The Court there held that where the language of a policy clause is ambiguous, the construction that is more favourable to the insured is to be preferred; the insurer who drafted the clause takes the consequences of any unclarity. The principle has been applied to exclusion clauses generally — including pre-existing disease clauses — in United India Insurance Co Ltd v M K J Corporation, (1996) 6 SCC 428, and in a long line of high-court and consumer-commission decisions.

The operational consequence in PED disputes is that an insurer who relies on an exclusion must show that the exclusion, as drafted, clearly covers the condition for which the claim is made. Where the policy language is ambiguous — whether the condition falls within the definition of pre-existing disease, whether the waiting period applies, whether the exclusion has been triggered — the construction is in favour of the insured. The post-2016 standardisation, which mandated standard definitions of pre-existing disease and standard exclusion language, has narrowed the scope for ambiguity in the policy language itself but has not eliminated it — the application of the standard definition to the facts of a particular case continues to throw up interpretive questions on which the contra proferentem rule operates.

Forums and remedies — Consumer Protection Act

A claim rejected on the ground of pre-existing disease is, in practice, contested before the consumer commissions. The Consumer Protection Act, 2019 includes insurance services within "service" under Section 2(42); the policyholder is a "consumer" under Section 2(7); the District Commission has jurisdiction over claims up to Rs 50 lakh under Section 34; the State Commission for claims between Rs 50 lakh and Rs 2 crore under Section 47; the National Commission for claims above Rs 2 crore under Section 58. The procedure is summary under Section 38, the limitation is two years from the cause of action under Section 69, and the appeal architecture is graded under Sections 41 and 51 with onward appeal to the National Commission and the Supreme Court. The consumer-forum route is the operational forum for PED disputes; the consumer commissions have decided a large body of cases in which the doctrinal frame of Satwant Kaur, Reliance Life Insurance v Rekhaben, Asha Goel and Sulbha Motegaonkar has been applied to particular fact-patterns.

The Insurance Ombudsman route — a quasi-judicial body constituted under the Insurance Ombudsman Rules, 2017 and administered by the Council for Insurance Ombudsmen — is the alternative forum for individual policyholder claims up to Rs 30 lakh. The Ombudsman's award is binding on the insurer if the policyholder accepts it within thirty days; it is not binding on the policyholder, who may approach the consumer commission or the civil court. The Ombudsman applies the same substantive doctrines as the consumer commissions but operates on a faster timeline and with lower procedural cost. A civil suit under Section 9 of the Code of Civil Procedure, 1908 is a third route, used in practice where the claim is large enough to warrant the higher procedural rigour. Writ jurisdiction under Article 226 of the Constitution is generally not available against private insurers — the Supreme Court has held that the contract of insurance is a private contract and disputes under it are not amenable to writ jurisdiction except where the insurer is a State within the meaning of Article 12 or where a public-law question is genuinely raised.

What the insurer must show — the operational checklist

An insurer who repudiates a health-insurance claim on the ground of pre-existing disease must show, on the established doctrinal frame, the following — first, that the proposer had the condition at the time of the proposal, or within the forty-eight-month look-back window mandated by the IRDAI definition; second, that the proposer had knowledge of the condition at the time of the proposal — knowledge that the proposer was diagnosed with it, treated for it, or advised about it (the Sulbha Motegaonkar standard requires objective evidence of knowledge); third, that the proposer did not disclose the condition in the proposal form or in any communication to the insurer; fourth, that the non-disclosure was material — that a prudent insurer would have considered the fact material in assessing the risk (the Satwant Kaur prudent-insurer test); fifth, that the policy is within the moratorium period, that is, fewer than eight continuous years from inception (the IRDAI 2019 framework). If the policy has crossed the moratorium, the insurer must additionally prove fraud — knowing and intentional misrepresentation, not merely innocent or negligent non-disclosure — and the burden of proving fraud is on the established civil-law standard, with the additional rigour the Supreme Court has applied where fraud is alleged.

The contestability lines, in practice, run on these five steps. The insured who disputes the repudiation cross-examines the medical examiner's evidence on the existence of the condition; tests the chain of inference from medical records to "knowledge" of the proposer; argues that the non-disclosure was not material because the condition has no causal connection with the claim (the Sulbha Motegaonkar and Manmohan Nanda line); invokes the moratorium where the policy has crossed eight years; and pleads contra proferentem on any ambiguity in the exclusion language. The insurer leads documentary evidence of the medical history, the proposal form, the policy schedule, the renewal history, and the surveyor's report; the consumer forum weighs the competing evidence on the civil standard. The outcome turns on whether the insurer has discharged the burden the Supreme Court placed on it in Asha Goel.

The disclosure duty in long-renewed policies

The eight-year moratorium has changed the operational calculus on long-renewed policies. Before the IRDAI 2019 framework, an insurer could repudiate a claim on the ground of non-disclosure even after many years of premium collection — the doctrine of uberrima fides operated for the life of the policy. After the moratorium, the eight-year window closes the contest on disclosure (subject to fraud), and the insurer must repudiate, if at all, on the basis of established fraud — the doctrinal cousin of Section 45 of the Insurance Act, 1938 which prevents life-insurance policies from being called in question on the ground of misstatement after three years. The change has shifted incentives — insurers underwrite more carefully at inception, ask more detailed questions, conduct medical examinations on higher sum-insured cases, and rely on the proposal-form record built at the start; insureds who have crossed the moratorium are operationally secure against PED-based repudiation; insurers who have accepted premium for eight years and now seek to repudiate must clear the fraud bar.

The interplay with portability is worth noting. A policyholder who switches from one insurer to another under the IRDAI Portability Guidelines, 2011 and its subsequent amendments carries forward the credits earned with the previous insurer for the purposes of waiting periods, including the PED waiting period and the moratorium period. The new insurer is required to accept the policy on the same terms as the outgoing policy in respect of pre-existing diseases that have already passed the waiting period and to count the years of cover for the purposes of the moratorium. The result is that an insured who has been continuously covered for eight years across multiple insurers, with valid portability transfers, is operationally within the moratorium with the new insurer — although the new insurer is entitled, under the underwriting guidelines, to test the proposal on its own and to take a fresh underwriting decision.

The unresolved questions

The post-2019 framework has settled most of the headline doctrinal questions but leaves a number of operational ones live. First — the interaction between the eight-year moratorium and the standardised exclusion clauses. The moratorium does not, on its terms, override permanent exclusions specified in the policy contract. An insurer who has a standard exclusion for a particular procedure or condition can continue to deny a claim under that exclusion even after the moratorium has run. The line between "ground of non-disclosure" (covered by the moratorium) and "ground of permanent exclusion" (not covered) is contested in particular fact-patterns where the exclusion incorporates the PED concept by reference. Second — the interplay between the IRDAI 2019 definition of pre-existing disease (forty-eight-month look-back, with diagnosis or medical advice or treatment) and the older policy language that contracts entered into before the 2019 amendment may carry. The Supreme Court has not yet definitively ruled on whether the 2019 standard definition applies retrospectively to a policy issued in 2015 and renewed since.

Third — the materiality test as applied to non-causally-connected conditions. The Sulbha Motegaonkar and Manmohan Nanda line suggests that a non-disclosure of a condition unrelated to the claim is not material; the Satwant Kaur and Reliance v Rekhaben line speaks of materiality at the underwriting stage, not at the claim stage. The reconciliation, broadly, is that materiality is tested at the underwriting stage — a prudent-insurer test — but the consumer commissions have, in practice, taken the absence of a causal connection as an indication that the materiality of the suppression was overstated by the insurer. The doctrinal question is live and is being worked out in the consumer-commission jurisprudence. Fourth — the construction of "any pre-existing disease" in policy clauses that are drafted to extend beyond the IRDAI definition. The standardisation framework binds the insurer to the IRDAI definition; an exclusion clause that extends the definition by contract is, on the contra-proferentem rule and on the regulatory architecture, vulnerable.

The doctrinal frame at the present time, taken together, places the burden firmly on the insurer. The proposer's disclosure duty under uberrima fides remains, but the insurer who seeks to repudiate must prove the existence of the condition at the time of the proposal, the proposer's knowledge of it, the non-disclosure, and the materiality on the prudent-insurer test — and must do so within the eight-year window before the moratorium closes the contest on disclosure. The contra-proferentem rule supplies a second layer of protection on ambiguous policy language. The consumer-commission route is the operational forum for the dispute. The doctrinal architecture is, by Indian-insurance standards, settled; the operational disputes are about the application of the architecture to fact-patterns, not about the architecture itself.